Friday, December 09, 2016 11:22:15 AM
I think the anti-pd-1 non-responder approach is in fact a great way for the company to garner some much-needed attention. Truly, what options do metastic melanoma patients have if they fail anti-pd-1 monotherapy, currently the gold standard for this indication?
I am encouraged by what I have seen so far with their melanoma results. The response durations and level of responses, i.e. complete responders, suggests to me that the treatment is definitely priming patients for checkpoint inhibitor use and they are essentially creating clinically effective in-situ vaccines as demonstrated by response durations. You simply do not see these types of responses in monotherapy anti-pd-1 data. And, you don't see as many complete responses even in combination treatments among all-comers.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM